Business Context and Reporting Period
This Form 8-K Current Report was filed by AtriCure, Inc. on August 11, 2019. The filing discloses the entry into a Material Definitive Agreement for the acquisition of SentreHEART, Inc. and a concurrent amendment to the Company's credit facility with Silicon Valley Bank.
Key Financial Metrics and Transaction Terms
Merger Agreement (SentreHEART Acquisition)
- Up-Front Consideration: Approximately $40 million in cash and AtriCure common stock.
- Contingent Consideration: Up to $260 million total, payable in cash and stock if specific milestones are met by December 31, 2026.
- $140 million tied to the aMAZE IDE clinical trial and PMA approval.
- $120 million tied to reimbursement milestones for SentreHEART devices.
- Share Issuance Cap: Maximum contingent shares limited to 19.9% of AtriCure's total shares outstanding.
- Conditions: Requires SentreHEART stockholder approval; does not require AtriCure stockholder approval or external financing.
SVB Credit Facility Amendment
- Term Loan Increase: Available advance increased from $40 million to $60 million.
- Interest Rate Adjustments:
- Term Loan: Increased to Prime Rate or 5.00% (whichever is greater) plus 0.75%.
- Revolving Line: Increased to Prime Rate or 5.00% (whichever is greater).
- Maturity Date: Extended to August 1, 2024 for both Term Loan and Revolving Line.
- Letter of Credit Sublimit: Increased to $5 million.
- Prepayment/Termination Fees: Modified to 4.00% (Term Loan) and 3.00% (Revolving Line) if paid/terminated before the first anniversary, decreasing thereafter.
Material Changes and Unusual Items
The filing does not provide comparative financial performance data (revenue, profit, cash flow) for the reporting period. The primary material change is the strategic shift via the SentreHEART acquisition, which introduces significant potential future liabilities contingent on clinical and regulatory success. Additionally, the cost of debt has increased due to the SVB amendment, though borrowing capacity has expanded.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated synergies, integration of operations, and market acceptance of combined products. Management has not provided specific financial guidance in this document.
Key Risks and Contingencies
- Transaction Completion: Risk of failing to satisfy merger conditions, including SentreHEART stockholder approval or material adverse effects.
- Regulatory and Clinical: Contingent payments depend on PMA approval and reimbursement, which are uncertain.
- Integration: Risks associated with integrating SentreHEART's technology and operations.
- Financial: Increased interest expense on the amended credit facility and potential dilution from stock issuance.
Investor Verification Checklist
- Verify the specific terms of the "Preferred Per Share" and "Common Per Share" Merger Consideration in the attached Merger Agreement (Exhibit 2.1).
- Confirm the current status of the aMAZE IDE clinical trial and reimbursement applications to assess the likelihood of the $260 million contingent payout.
- Review the amended Loan and Security Agreement (Exhibit 10.1) for detailed covenants regarding the minimum liquidity ratio.
- Monitor the outcome of the SentreHEART stockholder vote required to consummate the merger.
- Assess the impact of the increased interest rates on AtriCure's future cash flow projections.